Bei Akademie registrieren
ACAD, US0042251084

ACADIA Pharmaceuticals stock: BofA keeps Buy rating, target at USD 31

Published on 11/12/2026 at 01:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BofA Securities kept its Buy rating on ACADIA Pharmaceuticals stock on Wednesday. The target keeps valuation in focus for investors.

Analyst rating stays positive

  • BofA Securities maintained its Buy rating on ACADIA Pharmaceuticals.
  • The recommendation was accompanied by a price target for the shares.
ACAD, US0042251084, Illustration mit AI erstellt.
ACAD, US0042251084, Illustration mit AI erstellt.

BofA Securities maintained its Buy rating on ACADIA Pharmaceuticals on Wednesday, November 11, 2026, and set a USD 31 price target, according to Futu News. Analyst Tazeen Ahmad was named in the report.

Target signals continued confidence

The unchanged Buy rating gives investors a fresh research reference after recent earnings and pipeline updates. The target stands well above the latest euro quotation, but the two figures use different currencies and are not directly comparable without an exchange-rate adjustment.

ACADIA Pharmaceuticals stock traded at 16.56 euros on Lang & Schwarz at 23:00 CET on Wednesday, November 11, 2026.

ACADIA Pharmaceuticals market details

  • Company: ACADIA Pharmaceuticals Inc.
  • ISIN: US0042251084
  • Ticker: ACAD
  • Trading venue: Lang & Schwarz
  • Price: 16.56 euros on November 11, 2026 at 23:00 CET
  • Analyst target: USD 31
  • Analyst rating: Buy, maintained by BofA Securities

The broader US market context is covered in current S&P 500 market reports.

More news and analyses on ACADIA Pharmaceuticals stock.

Disclaimer...
en | US0042251084 | ACAD | boerse | 70494543 | bgmi